Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a pioneering company in the field of synthetic biology, specializing in the industrial-scale production of synthetic DNA. At the heart of its operations is a proprietary semiconductor-based DNA synthesis platform, which represents a significant advancement over traditional methods. By synthesizing DNA on a 10,000-well silicon platform instead of conventional 96-well plastic plates, Twist Bioscience achieves unprecedented levels of efficiency, scalability, and cost-effectiveness. This innovation enables the production of high-quality synthetic DNA at a faster pace and lower cost, addressing key inefficiencies in the industry.
The company's product offerings include a wide range of synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. These tools are critical for applications across multiple industries, including pharmaceutical research, personalized medicine, agriculture, sustainable chemical production, and emerging fields like DNA data storage and in vivo diagnostics. Twist Bioscience's platform not only accelerates research and development but also empowers organizations to innovate in areas such as biodetection and bioengineering.
Operating primarily in the United States, Twist Bioscience serves a diverse customer base that includes biotech firms, pharmaceutical companies, academic institutions, and industrial research organizations. Its business model revolves around direct sales of synthetic DNA products and services, catering to the growing demand for advanced biological engineering solutions. By leveraging its cutting-edge technology, the company has established itself as a critical enabler in the synthetic biology ecosystem.
The broader synthetic biology industry is characterized by rapid innovation and significant growth potential, driven by advancements in genomics, bioinformatics, and sustainable technologies. Twist Bioscience's focus on high-throughput, cost-effective DNA synthesis positions it as a key player in this dynamic market. However, the company faces competition from other DNA synthesis providers, necessitating continuous investment in research and development to maintain its technological edge.
What sets Twist Bioscience apart is its commitment to overcoming traditional limitations in DNA synthesis. By utilizing silicon-based manufacturing, the company not only enhances production efficiency but also expands the possibilities for synthetic biology applications. This unique approach underscores its role as a transformative force in the industry, enabling researchers and organizations to unlock new opportunities in science and technology.
In summary, Twist Bioscience combines technological innovation with a deep understanding of synthetic biology to deliver high-quality DNA synthesis solutions. Its proprietary platform and diverse product offerings make it a vital partner for industries seeking to harness the power of engineered biology. As the demand for synthetic DNA continues to grow, Twist Bioscience remains at the forefront of enabling groundbreaking advancements across multiple sectors.
Twist Bioscience Corporation (NASDAQ: TWST) has announced its upcoming financial results for the fiscal 2023 second quarter, which ended on March 31, 2023. The results will be released before the market opens on May 5, 2023. A conference call is scheduled for 8:00 a.m. Eastern Time on the same day, where the company's financial performance and business updates will be discussed.
The press release will be available on the company's website in the Investor Relations section prior to the call. Twist Bioscience specializes in high-quality synthetic DNA manufacturing using a proprietary silicon-based platform, focusing on various applications across healthcare, agriculture, and genomics.
Twist Bioscience Corporation (NASDAQ: TWST) announced the launch of its integrated offering of antibody discovery services, combining its synthetic libraries, AI machine learning, and in vivo immunization through the acquisition of Abveris. This premium service aims to provide optimized, development-ready antibody candidates, enhancing throughput and speed for clients. The initiative is led by Tracey Mullen, newly appointed Senior VP of Biopharma. The offering will be showcased at the Festival of Biologics from March 20-22, 2023. The integrated approach facilitates improved discovery and optimization of diverse antibody formats, promoting success in preclinical development.
Twist Bioscience Corporation (NASDAQ: TWST) announced key presentations by CEO Emily M. Leproust and CFO Jim Thorburn at upcoming investor conferences. They will participate in the Cowen 43rd Annual Healthcare Conference on March 6-7, 2023, with a fireside chat on March 7 at 1:30 p.m. ET. The Barclays Global Healthcare Conference will occur on March 14, 2023, featuring a fireside chat at 2:05 p.m. ET. Both events will be webcasted live and available for replay for 30 days. Twist Bioscience specializes in synthetic DNA manufacturing, with applications across healthcare, agriculture, and more.
Twist Bioscience Corporation (NASDAQ: TWST) announced the discovery of alpaca-derived VHH antibodies via a novel in vivo screening method on the Beacon platform. The study, published in BioRxiv, showcases methodology that efficiently screens single B cells for specific heavy-chain-only antibodies, particularly targeting human prostate specific membrane antigen (PSMA). All VHH-Fc candidates demonstrated nanomolar affinity for PSMA. This approach allows for improved antibody optimization and potential therapeutic applications, leveraging Twist's advanced sequencing technologies.
Twist Bioscience (NASDAQ: TWST) announced early access to its enhanced Whole Genome Sequencing (eWGS) solution for non-human genomics at the AGBT 2023 meeting in Hollywood, Florida. This innovative solution allows researchers to obtain simultaneous low-pass whole genome data with deep coverage of specific regions, enhancing cost-effectiveness and high throughput. The eWGS workflow uses a modified 96-plex library preparation kit, facilitating the sequencing of 96 samples in a single tube, aimed at improving resolution and flexibility in agricultural genomics. Additionally, Twist will present three posters on next-generation sequencing and reference standards during the conference.
Twist Bioscience Corporation (NASDAQ: TWST) reported a strong start to fiscal 2023, with revenue of $54.2 million in the first quarter, reflecting a 29% increase from $42.0 million in the same quarter last year. Total orders rose to $64.7 million, a 30% increase year-over-year. Despite a net loss of $41.8 million, improvements were noted in expenses: Selling, General and Administrative costs dropped from $51.1 million to $42.3 million. The company shipped products to 2,060 customers and launched key partnerships in biopharma and DNA storage, showcasing robust growth and innovation in its core business areas.
Twist Bioscience Corporation (NASDAQ: TWST) announced the shipment of initial products from its new manufacturing facility in
Twist Bioscience Corporation (NASDAQ: TWST) will release its fiscal 2023 Q1 financial results on February 3, 2023, before market opening. A conference call and live audio webcast will follow at 8:00 a.m. ET, aimed at discussing the results and providing business updates. The press release with details will be available on Twist's Investor Relations page.
Twist is a leader in synthetic biology and genomics, utilizing a cutting-edge DNA synthesis platform built on silicon technology, serving various sectors including healthcare and agriculture.
Twist Bioscience (TWST) and Centogene (CNTG) have launched three next-generation sequencing target enrichment panels aimed at advancing research and diagnostics for rare diseases and hereditary cancers. These panels enhance the precision of genetic sequencing and are based on data from Centogene's Biodatabank, which includes nearly 700,000 patients. The products include the Twist Alliance CNTG Exome Panel, CNTG Rare Disease Panel, and CNTG Hereditary Oncology Panel. This collaboration is expected to improve diagnostic capabilities worldwide, facilitating earlier disease detection and treatment development.
Twist Bioscience (NASDAQ: TWST) has announced a research collaboration with Astellas Pharma Inc to discover antibodies targeting diseases with high unmet medical needs. This partnership, following a successful initial collaboration, highlights Twist's antibody discovery capabilities through its Library of Libraries. Under the agreement, Twist will receive an upfront payment, project-specific research fees, and earn up to
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience specialize in?
How does Twist Bioscience's technology differ from traditional DNA synthesis methods?
What industries benefit from Twist Bioscience's products?
How does Twist Bioscience generate revenue?
Who are Twist Bioscience's main competitors?
What makes Twist Bioscience unique in the synthetic biology market?
What applications does Twist Bioscience's technology support?
Where does Twist Bioscience derive most of its revenue?
